Cold-fX makers misled public, case should receive class-action approval: lawsuit

Cold-fX lawsuit seeks class-action approval

VANCOUVER — The makers of Cold-fX are in court fighting allegations they ignored their own research and misled consumers about the short-term effectiveness of the popular cold and flu remedy.

Valeant Pharmaceuticals (TSX:VRX) was in British Columbia Supreme Court on Monday, opposing an application to grant the lawsuit class-action status.

Vancouver Island resident Don Harrison launched a claim in 2012 against Valeant and its subsidiary, Afexa Life Sciences, over advertising saying that Cold-fX offered “immediate relief of cold and flu symptoms” if taken over a three-day period at the first sign of illness.

Harrison’s notice of claim said Valeant and Afexa continued to “knowingly or recklessly” promote Cold-fX despite evidence the natural-health product only had a possible positive impact after being taken daily for prolonged periods of two-to-six months.

“The gist of the case is that people paid money for a worthless product … and the money they spent should be returned,” said Harrison’s lawyer, John Green, in a interview.

Valeant also unnecessarily exposed its customers to a health threat by distributing a useless drug with a risk of adverse side effects, he said.

The Laval, Que.,-based company denied the accusations in a statement and said it will fight the application for class-action certification.

“Valeant believes the suit is without merit and is vigorously defending this matter,” said the document.

None of the allegations have been tested in court.

Afexa is the original manufacturer and licence holder of Cold-fX and was bought by Valeant in 2011.

Valeant has been marred by a succession of controversies in recent months that have sapped its stock value and hammered its reputation, leading the CEO of the embattled Quebec drugmaker to step down last month.

The series of setbacks include gouging customers by hiking drug prices and filing misstated earnings, the latter of which it blames on its former chief financial officer.

Green also alleged Valeant and Afexa kept quiet about an internal study conducted in the early 2000s that contradicted the health claims around Cold-fX.

“The defendants knew at least as early as 2004, when they had a study done themselves, that Cold-fX might be even less effective than a placebo,” he said. 

“The study actually showed the placebo to be more effective at relieving (some) cold symptoms than Cold-fX.”

The study found the product effectively reduced the severity of a runny nose during the early days of a respiratory infection, but that it had limited efficacy in treating other symptoms, particularly a cough and stuffy nose.

If the case receives class-action approval, anyone who bought Cold-fX for the short-term relief of cold and flu symptoms will be able to apply to a fund that will be created to get their money back, said Green.

He estimated the total to be refunded would amount to about $500 million. That calculation uses $50 million per year in estimated revenues for Valeant from Cold-fX, then assumes a 100-per-cent markup, over a five-year time period.

Because of differences in provincial law, a court victory in B.C. wouldn’t allow people outside the province who bought Cold-fX to make a claim, said Green. For that reason, an identical lawsuit has been launched in Saskatchewan, where a positive ruling would apply to everyone across the country.

A successful judgment from a B.C. representative plaintiff could be taken to Saskatchewan to bolster the case in that province, he said.

Valeant is expected to begin its defence on Tuesday or Wednesday.

— Follow @gwomand on Twitter

Geordon Omand, The Canadian Press

Just Posted

Hundreds rally in support of horse carriages outside Victoria City Hall

Crowd angry with Coun. Ben Isitt’s motion to ban local horse carriage industry

Rifflandia Festival cancelled for 2019

Early Bird tickets can be refunded at point of purchase, or held and redeemed for 2020

Five-month bridge closure poses early impacts on drivers during rush hour

Construction began Tuesday on the crossing commonly known as the Bay Street bridge

New virgin queen headlines ‘Bee Day’ at Saanich sanctuary

Taste bee spit and check out the hive at Swan Lake Christmas Hill Nature Sanctuary this Sunday

Mom who lost son to brain tumour in March joins the 24th annual Brain Tumour Walk

The Brain Tumour Walk takes place at the University of Victoria on Sunday, May 26

VIDEO: Canadian, U.S. Coast guards run oil spill response drills

20 vessels were on the water to practice international response methods

Greater Victoria wanted list for the week of May 21

Greater Victoria Crime Stoppers is seeking the public’s help in locating the… Continue reading

POLL: Were you satisfied with the Game of Thrones series finale?

Millions gathered in front of their televisions Sunday night to watch the… Continue reading

Raptors beat Bucks 105-99 to move within 1 game of NBA Finals

Leonard scores 35 as Toronto takes 3-2 series lead over Milwaukee

B.C. Supreme Court dismisses review around ferry workers’ right to strike

B.C. Ferry and Marine Workers’ Union collective agreement expires November 2020

Young Victoria distillery earns prestigious Scotch awards

Scottish influences range from techniques to ‘kilted tours’ at award-winning business

Municipalities protest after B.C. declares marijuana crops ‘farm use’

UBCM president seeks answers in letter to John Horgan government

CMHC defends mortgage stress test changes amid calls for loosening rules

Uninsured borrowers must now show they could service their mortgage if rates rose two per cent

Brewpub offers ‘boat valet’ for paddlers during Surfrider celebration tonight

Free ‘Surf Formal’ evening features a local art auction, door prizes, live music

Most Read